Registration for a live webinar on 'Innovative Vaccines and Viral Pathogenesis: Insights from Recent Monkeypox (Mpox) Research' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Gene therapy
- Liver transplantation vs. Gene therapy for genetic diseases
- Liver-directed gene therapy
- Gene therapy strategies (1)
- Strategies for liver-directed gene therapy: ex vivo
- Ex vivo liver-directed gene therapy: limitations
- Liver repopulation
- Strategies for liver-directed gene therapy: in vivo
- Vectors for in vivo liver-directed gene therapy
- Human adenovirus serotype 5
- Ornithine transcarbamylase deficiency clinical trial
- Follow up to the OTC deficiency clinical trial
- AAV vectors
- Hemophilia
- How much liver transduction is needed in other disorders?
- Hemophilia B gene therapy (AAV8) clinical trial
- In vivo gene therapy
- Liver-directed gene therapy clinical trials
- Open issues for AAV-mediated liver gene therapy
- Overcoming pre-existing NAbs against AAV
- CTL immune response against AAV transduced hepatocytes
- Liver growth and vector genome dilution
- AAV and genotoxicity
- Clonal expansion of transduced hepatocytes
- Challenges for gene delivery to diseased livers
- Transduction of liver and zonation
- In vivo liver-directed gene therapy by lentiviral vectors
- Non-viral vectors
- Gene therapy strategies (2)
- Gene silencing
- Gene therapy strategies (3)
- Genome editing
- Promoterless, nuclease-free genome editing in methylmalonic acidemia
- Conclusions & future prospects
- Thank you
Topics Covered
- Liver metabolism
- Gene therapy strategies
- Inborn errors of metabolism
- Biochemical genetics
- Viral vectors for gene therapy in the liver
- In vivo gene therapy
- Viral vectors and genotoxicity
- Non-viral vectors
Links
Categories:
Therapeutic Areas:
Talk Citation
Brunetti-Pierri, N. (2022, February 23). Liver-directed gene therapy [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved November 21, 2024, from https://doi.org/10.69645/ICTM5619.Export Citation (RIS)
Publication History
Financial Disclosures
- Prof. Nicola Brunetti-Pierri has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
A selection of talks on Gastroenterology & Nephrology
Transcript
Please wait while the transcript is being prepared...
0:00
Hello. Welcome to my talk on
Liver-Directed Gene Therapy.
My name is Nicola
Brunetti-Pierri and I work at
the Telethon Institute
of Genetics and Medicine
and at Federico II
University in Naples, Italy.
0:16
The focus of this talk
is on gene therapy-
that is the treatment of diseases using
nucleic acids, either DNA or RNA.
Viruses are typically used
as a tool for transferring
therapeutic genes
because viruses have
the natural ability to transfer genetic
material to the infected cells.
The viruses are modified in
the laboratory to preserve
their natural capacity for
transferring genetic material,
but the harmful genes of
the viruses are deleted.
The viral vector
typically binds to
a receptor on the
plasma membrane,
is internalized and
coated in the cytoplasm,
and then the viral genome
migrates into the nuclei
where it can stay as
an episome, or it can
integrate into the
chromosomal DNA. Either as
an episomal or as an
integrated vector,
the viral vector genome can then
produce the therapeutic
gene product.
1:17
Liver transplantation is used for the
treatment of several liver metabolic diseases.
Liver transplantation is
performed with the goal of
correcting a single gene
defect by replacing
thousands of genes that
are from a donor organ.
The goal of gene
therapy instead,
is to target correction of the
disease-causing gene defect.